3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
1
Neoplasms
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Adenocarcinoma
1
Interventions
Gemcitabine
39
Cisplatin
24
Oxaliplatin
15
pembrolizumab
12
Capecitabine
12
Fluorouracil
9
Leucovorin
7
Albumin-Bound Paclitaxel
7
lenvatinib
6
Radiofrequency Ablation
6
Panitumumab
6
130-nm albumin-bound paclitaxel
6
Irinotecan
5
Bevacizumab
5
durvalumab
4
Taxes
4
Nivolumab
4
Hepatectomy
4
Drug Therapy
4
tremelimumab
3
apatinib
3
Radiosurgery
3
Platinum
3
Injections
3
Floxuridine
3
Cetuximab
3
1,2-diaminocyclohexaneplatinum II citrate
3
trametinib
2
spartalizumab
2
sintilimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Cholangiocarcinoma
×
gemcitabine-oxaliplatin regimen
×
Clear all
NCT01267344
2016-05-04
BTC
National Health Research Institutes, Taiwan
Phase 2
Completed
122 enrolled